Precipio, Inc. announced it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio's HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physician owned laboratories.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.025 USD | -2.43% | -2.82% | -7.31% |
Apr. 01 | Transcript : Precipio, Inc. - Special Call | |
Mar. 29 | Precipio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
103.2 USD | -0.58% | -4.60% | 25.1B | ||
6.025 USD | -2.43% | -2.82% | 8.62M | ||
1st Jan change | Capi. | |
---|---|---|
-7.31% | 8.62M | |
-12.91% | 19.08B | |
-46.21% | 2.65B | |
+18.15% | 1.87B | |
-3.12% | 1.61B | |
+23.78% | 1.21B | |
-10.69% | 1.02B | |
-20.89% | 905M | |
-18.10% | 682M | |
-7.14% | 716M |
- Stock Market
- Equities
- PRPO Stock
- News Precipio, Inc.
- Precipio, Inc. and Cardinal Health Sign Distribution Agreement for Its HemeScreen®? Portfolio of Molecular Assays for Cancer